Nephritis Clinical Trials

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for ...

Local doctors are looking for people with Lupus Nephritis for clinical research studies of an investigational medication. Compensation provided for time and travel!

Systemic lupus erythematosus (SLE) is a chronic, debilitating autoimmune disease that is characterized by the presence of autoreactive B cells and elevated levels of autoantibodies, which directly damage the body’s cells and tissues. SLE can affect multiple organ systems simultaneously or sequentially, and follows an unpredictable clinical course where periods ...

The drug being tested is called belimumab. It is a prescription medicine to treate active systemic lupus erythematosus who are receiving other lupus medicines. The purpose of the study is to find out if belimumab is effective and safe in treating patients with active lupus nephritis who are receiving other ...

Lupus nephritis is a severe form of systemic lupus erythematosus (SLE) with active disease in the kidneys. SLE is a complex disease in which the body's own immune system attacks some of the body parts: the skin, the joints, the kidneys, the nervous system, the heart, the lungs and the ...

People with Lupus Nephritis are asked to participate in a research study being conducted by North Shore Long Island Jewish Health System. Patient Inclusion Criteria: You may be eligible to participate in this study if you: Are between the ages of 18 and 75 years Have been diagnosed with Lupus ...

People with active lupus nephritis are asked to participate in a clinical research study being conducted by Feinstein Institute for Medical Research.

Primary Objective: To assess the efficacy of Orelvo (voclosporin) compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis (LN) Secondary Objective: To assess the safety and tolerability of Orelvo over 52 weeks compared with placebo in subjects with active LN

Detailed Description: ASTOR is envisioned as a permanent organization sustained by private philanthropic and public funding sources. Recruitment of participants for the registry will consist of three approaches. First, pediatric nephrologists in the United States and Canada will be invited to participate in ASTOR. Activities of participating investigators will include ...

There is accumulating evidence that tacrolimus (TAC) could serve as an effective medication for the treatment of lupus nephritis (LN). TAC is a calcineurin inhibitor, which is a key component in first-line combination immunosuppressive regimens after kidney transplantation, based on its proven efficacy in the prevention and treatment of allograft ...